Anthranilic acid-based compound, and Pin1 inhibitor, therapeutic agent for inflammatory diseases and therapeutic agent for cancer that use the same
The purpose of the invention is to develop, as drug-candidate compounds, a group of novel compounds having the activity of inhibiting functions of Pin1. The invention provides: a compound represented by formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic or prophylactic agent for inflammatory diseases, a therapeutic or prophylactic agent for cancer, and a therapeutic or prophylactic agent for adiposity that use said compound/salt.
1. A compound represented by the Formula (I), or a salt thereof:
wherein at least one of the R 1 or R 2 represents an optionally substituted naphthyl group, an optionally substituted quinolyl group, or an optionally substituted phenoxy phenyl group;
either R 1 or R 2 represents, if not any of the above-described groups, an optionally substituted aryl group, or an optionally substituted monocyclic heterocyclic group;
R 3 represents a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group; and
X represents a single bond, —CO— group, —CO—O—CH 2 — group, —CO—CH 2 —O— group, —SO 2 — group, —CH 2 —CO—NH— group, —CH 2 —CO— group, or —CH 2 — group.
2. The compound or a salt thereof according to claim 1 , wherein at least one of R 1 or R 2 represents an optionally substituted naphthyl group.
3. The compound or a salt thereof according to claim 2 , wherein R 1 represents an optionally substituted naphthyl group.
4. The compound or a salt thereof according to claim 1 , wherein R 3 represents a hydrogen atom or a methyl group.
5. A Pin1 inhibitor comprising the compound or a salt thereof according to claim 1 .
6. A pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof according to claim 1 and a pharmaceutically acceptable carrier.
7. A therapeutic or prophylactic agent for the treatment or prevention of an inflammatory disease associated with fibrosis, comprising the compound or a pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient.
8. The therapeutic or prophylactic agent according to claim 7 , wherein the inflammatory disease associated with fibrosis is non-alcoholic steatohepatitis, inflammatory bowel disease, or pulmonary fibrosis.
9. The therapeutic or prophylactic agent according to claim 7 , further comprising an active ingredient of at least one additional drug for the treatment or prevention of the inflammatory disease associated with fibrosis.
10. A method of treating or preventing an inflammatory disease associated with fibrosis, comprising administering the therapeutic or prophylactic agent according to claim 7 , in combination with at least one additional drug for the treatment or prevention of the inflammatory disease associated with fibrosis.
11. A therapeutic or prophylactic agent for the treatment or prevention of cancer, comprising the compound or a pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient.
12. The therapeutic or prophylactic agent according to claim 11 , wherein the cancer is colon cancer or prostate cancer.
13. The therapeutic or prophylactic agent according to claim 11 , further comprising an active ingredient of at least one additional drug for the treatment or prevention of cancer.
14. A method of treating or preventing cancer, comprising administering the therapeutic or prophylactic agent according to claim 11 , in combination with at least one additional drug for the treatment or prevention of cancer.
15. A method of preparing a medicament for the treatment or prevention of cancer, comprising combining a pharmaceutically acceptable carrier and a therapeutic or prophylactic amount of the compound or a pharmaceutically acceptable salt thereof according to claim 1 .
16. A method of treating or preventing cancer, comprising administering the compound or a pharmaceutically acceptable salt thereof according to claim 1 to a patient in need thereof.
17. A therapeutic or prophylactic agent for the treatment or prevention of obesity, comprising the compound or a pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient.
18. A therapeutic or prophylactic agent according to claim 17 , further comprising an active ingredient of at least one additional drug for the treatment or prevention of obesity.
19. A method of treating or preventing obesity, comprising administering the therapeutic or prophylactic agent according to claim 17 , in combination with at least one additional drug for the treatment or prevention of obesity.
20. A method of preparing a medicament for the treatment or prevention of obesity, comprising combining a pharmaceutically acceptable carrier and a therapeutic or prophylactic amount of the compound or a pharmaceutically acceptable salt thereof according to claim 1 .
21. A method of treating or preventing obesity, comprising administering the compound or a pharmaceutically acceptable salt thereof according claim 1 to a patient in need thereof.
22. A method of preparing a medicament for the treatment or prevention of an inflammatory disease associated with fibrosis, comprising combining a pharmaceutically acceptable carrier and a therapeutic or prophylactic amount of the compound or a pharmaceutically acceptable salt thereof according to claim 1 .
23. A method of treating or preventing an inflammatory disease associated with fibrosis, comprising administering the compound or a pharmaceutically acceptable salt thereof according to claim 1 to a patient in need thereof.
24. The compound or a salt thereof according to claim 2 , wherein R 2 represents an optionally substituted naphthyl group.